CC 42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle.- Cocrystal Pharma
Cocrystal Pharma, Inc.’s novel, broad-spectrum antiviral CC 42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently completed in vitro studies. CC 42344 is a new class of antiviral drugs designed to block essential steps in the replication and transcription of the influenza A virus.
Cocrystal is conducting an influenza A Phase IIa clinical study with orally administered CC 42344 and expects to report topline results in the second half of 2024. This study is evaluating the safety, tolerability, antiviral and clinical benefits in influenza A infected subjects. In late 2022 Cocrystal reported favorable safety and tolerability results from a Phase I study in healthy volunteers.
Cocrystal demonstrated the potential efficacy of CC 42344 against the new avian flu strain with the recently published genome sequence for H5N1. Using its proprietary structure-based platform, Cocrystal created a high-resolution crystal structure of this avian PB2 protein and confirmed that CC 42344 binds to its highly conserved PB2 region. The in vitro data were generated testing CC 42344 against the avian H5N1 PB2 protein and further support CC 42344’s activity similar to that of Cocrystal’s data with pandemic and seasonal influenza A.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.